Overall, our results suggest that CTEN contributes to tumor progression in canine SCC, therefore revealing CTEN’s potential as a biomarker and a therapeutic target for canine SCC, as well as its possible value in histological grading of invasive fronts. The gene discussed is TNS4; the disease is neoplasm.